Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases ...

Biogen Inc. (NASDAQ:BIIB), a leader in biotechnology, announced the appointment of Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller, effective March 1, 2025 ...

Biogen Hits Lowest Stock Price Since 2013 as Leqembi Uptake Lags Biogen CEO Chris Viehbacher at JPM25 said that the pharma remains fully committed to the Alzheimer’s disease space and its therapeutic ...

1:50 p.m. ET In the wake of the FDA's approval for Eli Lilly’s Alzheimer’s disease treatment last year, Biogen CEO Chris Viehbacher said his company is ready for the competition. Speaking ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...